In 2019, bacterial antimicrobial resistance (AMR) directly killed 1.27 million people and played a role in 4.95 million deaths worldwide, according to a landmark study published in The Lancet. That makes drug-resistant infections deadlier than HIV/AIDS (864,000 deaths that year) and malaria (643,000 deaths). Unlike a sudden pandemic that dominates headlines, AMR kills steadily, quietly, and in increasing numbers every year.
By 2050, the O'Neill Review commissioned by the UK government projects that AMR could kill 10 million people annually if current trends continue. That would make it the leading cause of death globally, surpassing cancer.
What exactly is antimicrobial resistance?
AMR occurs when bacteria, viruses, fungi, or parasites evolve to survive the drugs designed to kill them. Antibiotics that once cleared an infection in days stop working. The microbe isn't "immune" in the way you might be immune to measles after vaccination. Instead, through random genetic mutation or horizontal gene transfer between bacteria, the organism acquires the ability to neutralize, pump out, or structurally dodge the drug.
Resistance is not a future threat. It's already here, and it's accelerating. Every year, the list of infections that no longer respond to first-line antibiotics grows longer. Some infections now resist every available drug.
Which superbugs should you know about?
Three drug-resistant organisms cause the most damage worldwide and represent the spectrum of AMR's threat.
MRSA (Methicillin-Resistant Staphylococcus aureus): Once confined to hospitals, MRSA now causes community-acquired infections in otherwise healthy people. In the US alone, MRSA caused an estimated 323,700 infections and 10,600 deaths in hospitalized patients in 2017, according to CDC data. Skin infections are the most common presentation. Severe cases invade the bloodstream, lungs, and bones. Treatment options have narrowed to vancomycin and a handful of newer agents, and vancomycin-resistant strains (VRSA) have already been documented.
XDR-TB (Extensively Drug-Resistant Tuberculosis): Standard tuberculosis treatment requires 4 drugs taken for 6 months. XDR-TB resists at least two of those drugs plus fluoroquinolones and at least one injectable agent. Treatment for XDR-TB can last 18-24 months, costs 25-50 times more than drug-susceptible TB, and succeeds in only about 40% of cases. In 2022, WHO estimated 450,000 new cases of rifampicin-resistant TB globally.
CRE (Carbapenem-Resistant Enterobacterales): The CDC has labeled CRE an "urgent threat." Carbapenems are often the last-resort antibiotics for severe gram-negative infections. When those fail, mortality rates for CRE bloodstream infections reach 40-50%. CRE is primarily a hospital-acquired pathogen, spreading through contaminated medical equipment, surfaces, and the hands of healthcare workers. It has been detected in hospitals on every continent.
How does resistance develop?
Two forces drive AMR: overuse in humans and massive use in agriculture. Both select for resistant organisms by creating environments where only drug-resistant bacteria survive and reproduce.
In human medicine, roughly 30% of antibiotic prescriptions in US outpatient settings are unnecessary, according to CDC estimates. The most common culprit is prescribing antibiotics for viral infections like colds, flu, and most sore throats. Antibiotics do nothing against viruses. But each unnecessary course kills susceptible bacteria in your body and gives resistant strains room to multiply.
Agriculture is the bigger driver by volume. An estimated 73% of all antibiotics sold globally are used in livestock, not to treat sick animals, but as growth promoters and prophylactics in crowded farming operations. In 2017, the US alone used approximately 11,000 tons of antibiotics in food-producing animals. Resistant bacteria from livestock reach humans through direct contact, contaminated meat, and environmental spread via water and soil.
Resistance genes move between bacterial species through plasmids, small rings of DNA that bacteria swap like trading cards. A resistance gene that evolves in a harmless gut bacterium on a pig farm can transfer to E. coli, then to Klebsiella, then to a pathogen that infects a hospital patient three continents away. Once a resistance gene exists, it spreads through the bacterial world with alarming efficiency.
Why aren't new antibiotics being developed?
Economics, not science, is the primary obstacle. Developing a new antibiotic costs approximately $1.5 billion and takes 10-15 years. Once approved, public health authorities immediately recommend limiting its use to preserve its effectiveness. A drug designed to be used as little as possible generates far less revenue than a drug for chronic conditions taken daily for years.
Between 2014 and 2023, nine antibiotic-focused biotech companies went bankrupt or abandoned their antibiotic programs. Achaogen, which developed plazomicin to treat CRE, filed for bankruptcy in 2019, less than a year after FDA approval. Revenue from the drug was $800,000 in its best quarter. Development had cost over $1 billion.
Of the 27 antibiotics in clinical development targeting WHO priority pathogens as of 2023, most are modifications of existing drug classes rather than truly novel mechanisms of action. The "push" model of funding (government grants for early research) has helped maintain the pipeline. But without "pull" incentives (guaranteed market rewards for approved drugs), pharmaceutical companies continue to allocate R&D budgets elsewhere.
Several proposals exist, including subscription-based payment models where governments pay a fixed annual fee for access to new antibiotics regardless of volume used. The UK piloted such a model in 2022. Scaling it globally remains a work in progress.
What does AMR mean for modern medicine?
Strip away effective antibiotics and modern medicine collapses backward by decades. Procedures you take for granted depend on the ability to prevent and treat bacterial infections.
Surgery: An estimated 39% of surgical site infections are already caused by resistant organisms. Without effective prophylactic antibiotics, routine operations like hip replacements, cesarean sections, and appendectomies become high-risk procedures. Pre-antibiotic surgical mortality rates were 10-40% for abdominal operations.
Cancer treatment: Chemotherapy deliberately suppresses the immune system. Patients undergoing chemotherapy develop life-threatening infections at rates of 10-50% depending on the regimen. If those infections resist treatment, cancer care becomes far deadlier. A 2019 study in The Lancet Infectious Diseases estimated that AMR already contributes to 27% of post-chemotherapy bloodstream infection deaths.
Organ transplantation: Transplant recipients take immunosuppressive drugs for life. Resistant infections are already the leading cause of death in the first year after transplant in many centers.
Childbirth: Maternal sepsis kills over 20,000 women annually in sub-Saharan Africa. As resistance to first-line antibiotics grows, that number will climb. Neonatal sepsis caused by resistant organisms already kills an estimated 214,000 newborns per year globally.
AMR doesn't just threaten people who get resistant infections. It threatens everyone who might need surgery, cancer treatment, or intensive care.
What can you do about AMR?
Individual actions won't solve a structural crisis, but they reduce your personal contribution to the problem and protect your own health.
Never pressure your doctor for antibiotics when you have a viral infection. Colds, most sore throats, acute bronchitis, and many sinus infections are caused by viruses. Antibiotics won't help. If your doctor says you don't need them, that's the correct answer.
When prescribed antibiotics, complete the full course. Stopping early because you feel better leaves the most resistant bacteria alive. Those survivors repopulate the infection site and can spread.
Choose meat raised without routine antibiotic use when possible. Labels like "raised without antibiotics" and "USDA Organic" (which prohibits routine antibiotic use in livestock) indicate lower-risk products. Consumer demand has already pushed several major US poultry producers to reduce antibiotic use by over 50% since 2015.
Get vaccinated. Vaccines prevent infections in the first place, reducing the need for antibiotics. The pneumococcal vaccine alone prevents an estimated 30,000 cases of invasive pneumococcal disease annually in the US, many of which would otherwise require antibiotics.
Practice good hygiene. Handwashing remains the single most effective measure against bacterial transmission in community settings. Five seconds of soap and water beats a course of antibiotics you shouldn't need.
Why does PandemicAlarm track AMR?
Because AMR is a pandemic in everything but name. It meets every epidemiological criterion: global distribution, rising mortality, transmissible agents, and inadequate countermeasures. It lacks only the sudden onset that triggers public alarm and political action.
PandemicAlarm monitors drug-resistant outbreaks alongside acute infectious disease events because they represent the same fundamental threat: pathogens outpacing our ability to control them. When a novel pathogen emerges with built-in drug resistance, AMR and pandemic preparedness become the same problem. Tracking both gives you a more complete picture of the microbial threats that actually endanger your health.